Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma
Robert Hanes(Oslo University Hospital), Ola Myklebost(Oslo University Hospital)
Cited by 20
Related Papers
Monogenic and polygenic determinants of sarcoma risk: an international genetic study
|The Lancet Oncology|2016|213
The tankyrase‐specific inhibitor <scp>JW</scp>74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines
|Cancer Medicine|2013|61
The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibition
|Frontiers in Immunology|2023|12